
AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

Bispecific IgG switch off SARS-CoV-2 escape variants
The team headed by Daniel Ruzek or Luca Varani from the University of Bellinzona and the Czech Academy of Sciences targeted two binding sites within...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

German Health Ministry to invest €6.2bn in vaccines
With the request to the national budget committee, which will decide on it tomorrow, Germany more than doubles the amount of money to be invested...

German antibodies in demand in USA
Initially, Seattle-based Just - Evotec Biologics will receive US$28.6m from the Defense Health Agency ("DHA") under a partnership announced...